In her 25 years at Mylan, including many years as a lobbyist in Washington before she became CEO, Bresch said pricing has changed little. High-deductible plans have proliferated, causing consumers to pay more out-of-pocket for drugs, doctor's office visits and hospital care. Employers as well as the government have pushed high-deductible plans, which tend to have lower premiums. “There’s a lack of understanding of where that full list prices goes and how it is divided in the system,” Bresch told Forbes Healthcare Summit attendees. “The pharmaceutical pricing system was not built on the idea on consumer engagement.”

Source: Forbes December 01, 2016 16:49 UTC